What is Neutropenia?
Neutropenia is defined as an absolute neutrophil count (ANC) below 1,500 cells/µL in Caucasian adults, with severe neutropenia occurring when the ANC falls below 500 cells/µL. 1, 2
Clinical Definition and Thresholds
The specific thresholds for neutropenia vary by severity and clinical context:
- General neutropenia: ANC <1,500 cells/µL (or <1,800 cells/µL per WHO criteria) 3
- Severe neutropenia: ANC <500 cells/µL 1, 2
- Profound neutropenia: ANC <100 cells/µL 1, 4
Important caveat: These thresholds vary by ethnicity and age. The 1,500 cells/µL cutoff applies primarily to Caucasian adults, and different populations may have naturally lower baseline neutrophil counts without increased infection risk 3.
Pathophysiology
Neutropenia results from three primary mechanisms:
- Decreased production in bone marrow (congenital neutropenia, chemotherapy-induced marrow suppression)
- Increased destruction or utilization (autoimmune neutropenia, drug-induced, viral infections)
- Abnormal distribution (sequestration in spleen or margination) 3, 5
Clinical Significance and Infection Risk
The risk of serious bacterial and fungal infections increases inversely with the neutrophil count, with the greatest risk occurring when ANC drops below 100 cells/µL. 2 The duration of neutropenia is equally critical—prolonged neutropenia (>7 days) carries substantially higher infection risk than brief episodes 1, 4.
Key infection risk factors include:
- Depth of neutropenia: Risk escalates dramatically below 500 cells/µL and especially below 100 cells/µL
- Duration: Prolonged neutropenia (>7 days) versus brief (<7 days)
- Rate of decline: Rapid drops in ANC increase infection susceptibility 2
Types of Neutropenia
Chemotherapy-Induced Neutropenia
The most common form in cancer patients, occurring as an expected consequence of cytotoxic therapy. Approximately 50-60% of patients who become febrile during neutropenia have an established or occult infection 2.
Severe Chronic Neutropenia
Includes congenital, cyclic, and idiopathic forms that require long-term management with G-CSF. These patients need different treatment approaches than those with chemotherapy-induced neutropenia 6, 7.
Clinical Manifestations
A critical pitfall: Signs and symptoms of infection are often diminished or absent in neutropenic patients due to the lack of inflammatory cells. Fever remains the primary and often only indicator of infection, though severely neutropenic patients may present afebrile or even hypothermic 2, 8.
Primary infection sites in neutropenic patients:
- Alimentary tract (mouth, pharynx, esophagus, bowel, rectum)
- Sinuses
- Lungs
- Skin and soft tissues 2
Risk Stratification
High-risk patients are defined as those with:
- Anticipated prolonged (>7 days) and profound neutropenia (ANC <100 cells/µL)
- MASCC score <21
- Significant medical comorbidities
- Unstable vital signs 1, 4
Low-risk patients have:
- Anticipated brief (<7 days) neutropenia
- MASCC score ≥21
- Few comorbidities
- Clinically stable presentation 1, 4
This distinction is critical because it determines whether patients require hospitalization with IV antibiotics versus potential outpatient oral therapy 4.
Management Principles
For febrile neutropenia (fever >38.5°C with ANC <500 cells/µL):
- High-risk patients require immediate hospitalization and empiric broad-spectrum IV antibiotics 1, 4
- Low-risk patients may be candidates for outpatient oral therapy 4
- Blood cultures (at least 2 sets) are mandatory before starting antibiotics 1
For severe chronic neutropenia:
- G-CSF is the established treatment, with doses adjusted to maintain ANC in the normal or low-normal range
- Idiopathic/cyclic neutropenia typically responds to 1-3 mcg/kg/day
- Congenital neutropenia requires higher doses (3-10 mcg/kg/day) 6, 7
Major concern with congenital neutropenia: These patients carry risk of progression to myelodysplasia and leukemia, with or without G-CSF treatment, emphasizing the need for careful long-term monitoring 6, 7.